Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

HALIFAX, NS, June 11, 2026 /CNW/ - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce the appointment of Michael A. Fleming to the board of directors of the Company.Michael A. Fleming joins board of clinical stage immuno-oncology company Sona Nanotech Inc.

Mr. Fleming served as Executive Vice President for commercial operations and subsequently as Chief Strategy Officer of Coherus BioSciences. During his tenure with Coherus, he led the company's transformation from a development-stage organization into a commercial oncology business, architecting the commercial strategy and launch of UDENYCA® (pegfilgrastim-cbqv), Coherus's first oncology asset and a market-leading pegfilgrastim brand.

Earlier in his career, Mr. Fleming held senior leadership roles at Elan, Genentech, and GlaxoSmithKline, where he directed global commercial strategy across multi-billion-dollar franchises and led numerous product launches across oncology, infectious disease, metabolic and specialty therapeutics.

Mark Lievonen, chair of Sona Nanotech commented: "We are delighted to welcome Michael as a director to the Company. Sona will benefit from Michael's significant biotech business experience built over a 35-year career guiding emerging life science companies through critical value inflection points including capital formation, clinical development, and strategic transactions. His direct experience with immune-oncology assets and the relationships he brings will be valuable ."

Michael Fleming commented, "I am delighted to join Sona at this exciting time as it builds on its recent, positive first-in-man clinical experience. Sona's Targeted Hyperthermia Therapy is a compelling potential treatment at a time when oncology is moving toward modulating the tumor microenvironment to engage the immune system in a less toxic way. I look forward to working with the board and management as Sona translates its gold nanorod platform into a therapeutics business."

About Sona Nanotech Inc. Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, that uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion, an approach aligned with the melanoma research community's active focus on converting immunogenically 'cold' tumors, which resist immunotherapy, into 'hot' tumors that the immune system can recognize and attack, thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Story Continues

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy; impact and effectiveness of Sona's THT cancer treatment; the timing and receipt of expected positive histological results supporting first-in-man treatment results obtained to date, including the anticipated design, conduct, and outcomes of the IGNITE-THT and PRIME-THT clinical studies; potential future applications of Sona's THT cancer treatment, including the estimated addressable patient population for early-stage melanoma; the timing and completion of Sona's proposed Canadian pilot study and Sona's preclinical and clinical study plans and the potential market impacts of such studies. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to secure the remaining required regulatory approvals for its clinical trials, including the ITA; enroll study participants in a timely manner, successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, the risk that THT may not prove to have the benefits currently reported and anticipated, and general economic, market, competitive and business conditions . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2026/11/c7355.html

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention.

Last month, the company reported better-than-expected first-quarter results, driven by strong HIV breast cancer drug Trodelvy and liver disease drug Livdelzi sales.

HIV business continues to maintain momentum, driven by solid performance of Biktarvy and Descovy, and incremental contributions from Yeztugo.

Biktarvy continues to be a dominant player in the HIV treatment market, holding more than 52% market share and retaining its position as the most prescribed therapy for both treatment-naïve and switch patients across major markets.

Gilead's HIV pre-exposure prophylaxis (PrEP) portfolio comprises daily oral Descovy and the first and only twice-yearly injectable Yeztugo.

Descovy's performance continues to be strong, primarily driven by higher demand and average realized price.

The FDA approval of injectable lenacapavir, a first-in-class capsid inhibitor (under the brand name Yeztugo), solidifies GILD's HIV portfolio. With a twice-yearly dosing schedule, the therapy offers meaningful adherence advantages over daily oral regimens and targets a broad patient population.

Following better-than-expected first-quarter results and improving market trends, Gilead raised its 2026 sales guidance for Yeztugo to $1 billion, signaling the product's potential to achieve blockbuster status in its first full year on the market.

Driven by increased Yeztugo sales expectations and strong first-quarter HIV performance, Gilead now projects total 2026 HIV sales growth of approximately 8% year over year, up from its prior guidance of 6% issued in February. The updated outlook includes an estimated 2% headwind related to the U.S. government's Medicaid drug pricing agreement and proposed Affordable Care Act changes.

The FDA accepted Gilead's new drug application for bictegravir/lenacapavir (BIC/LEN) for virologically suppressed people living with HIV under priority review, setting a target action date of Aug. 27, 2026.  A potential approval of BIC/LEN will further bolster its HIV portfolio.

Looking ahead, with no significant loss-of-exclusivity (LOE) events expected until 2036, Gilead's HIV franchise is well positioned for sustained long-term growth, supported by the potential launch of up to seven new HIV therapies by 2033.

GILD has also collaborated with Merck MRK to advance its HIV pipeline further.

Gilead and Merck recently announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, evaluating investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir.

Story Continues

The investigational regimen combines Merck's islatravir, a next-generation nucleoside analog that inhibits HIV replication through multiple mechanisms, including reverse transcriptase translocation inhibition, with Gilead's lenacapavir.

Both studies met the primary efficacy endpoint at week 48. Following the positive phase III results, Gilead and Merck intend to submit the ISLEND trial data to regulatory authorities worldwide and present detailed study findings at an upcoming scientific conference.

Gilead presented encouraging phase I data for the long-acting integrase inhibitor GS-3242 in February. Additional data expected later this year could support the development of a twice-yearly injectable regimen combining GS-3242 with lenacapavir.

Approval of additional treatments should strengthen its dominant HIV franchise.

Competition for GILD's HIV Business

The HIV treatment landscape is dominated by many bigwigs, such as GSK plc GSK and Merck, apart from GILD.

HIV sales account for a major chunk of GSK's Specialty Medicines portfolio. GSK continues to grow its HIV business, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato. The solid growth from these drugs has helped GSK combat the decline in Triumeq sales.

MRK markets doravirine for treating adults with HIV-1 in the United States, either as a monotherapy under the brand name Pifeltro or as part of the single-tablet combination regimen under the brand name Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate).

MRK recently won FDA approval of Idvynso, a once-daily, two-drug single-tablet regimen containing doravirine (100 mg) and islatravir (0.25 mg), for adults living with HIV-1 who are virologically suppressed on a stable antiretroviral regimen. The approval covers patients with no history of treatment failure and no known resistance-associated mutations to doravirine, allowing them to switch from their current HIV therapy.

Merck is also evaluating a once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in treatment-naïve adults with HIV-1 infection.

GILD's Price Performance, Valuation and Estimates

Shares of GILD have gained 2.3% year to date against the industry's decline of 3.1%.Zacks Investment Research

Image Source: Zacks Investment Research

Going by the price/earnings ratio, GILD's shares currently trade at 33.39X forward earnings, higher than its mean of 11.87X and the large-cap pharma industry's 17.59X.Zacks Investment Research

Image Source: Zacks Investment Research

The consensus estimate for 2026 has deteriorated sharply over the past 30 days, shifting to a loss of 79 cents per share from projected earnings of $4.32 per share. The estimate for 2027 has also edged lower to $9.53 per share from $9.57 during the same period.Zacks Investment Research

Image Source: Zacks Investment Research

While Gilead's recent aggressive dealmaking strategy strengthens its long-term pipeline and growth potential, the sizable upfront payments and integration-related costs are pressuring near-term profitability.

GILD currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

Barclays upgraded Oscar Health(OSCR) to Overweight from Equal Weight with a price target of $35, up from $30. The firm says that with "single-line exposure" to the individual Affordable Care Act market, Oscar offers the "most direct leverage to a potential multi-year multiple re-rating." Evercore ISI upgraded Devon Energy(DVN) to Outperform from In Line with a $54 price target. The better-than-expected mid-month update underscores not just improving capital efficiency, but also a "surprise, explicit comment on the portfolio review, with the key word being 'expeditiously'," the firm tells investors. JPMorgan upgraded Illumina (ILMN) to Overweight from Neutral with a price target of $185, up from $125. JPMorgan cites Illumina's customer "stickiness" and its favorable recent customer survey for the upgrade. UBS upgraded BorgWarner (BWA) to Buy from Neutral with a price target of $95, up from $61. The company is the best positioned auto supplier to benefit from non-auto opportunities, the firm tells investors in a research note. UBS upgraded Cava Group(CAVA) to Buy from Neutral with a price target of $90, up from $85. The company offers an attractive same-store-sales catalyst path with industry-leading unit growth, the firm tells investors in a research note.

Top 5 Downgrades:

RBC Capital downgraded Nike (NKE) to Sector Perform from Outperform with a price target of $50, down from $70. While the company's turnaround under CEO Elliott Hill is making progress, it is "slower and narrower" than expected, the firm tells investors in a research note. Guggenheim downgraded Nuvalent (NUVL) to Neutral from Buy with a price target of $124, down from $151, citing the proposed acquisition by GSK (GSK) for $124 per share in an all-cash transaction. UBS, TD Cowen, Barclays, and Truist also downgraded Nuvalent to Neutral-equivalent ratings. Berenberg downgraded Nutrien (NTR) to Hold from Buy with a price target of $65, up from $61. The company is likely to deliver another year of solid earnings, but the firm is concerned that consensus estimates "will continue to anchor on earnings levels that remain above mid-cycle." Wolfe Research downgraded Taylor Morrison(TMHC) to Peer Perform from Outperform without a price target following the announced acquisition by Berkshire Hathaway (BRK.A) for $72.50 per share. Truist downgraded Bill (BILL) to Hold from Buy with a price target of $35, down from $45. The firm finds it increasingly unlikely that a software-as-a-service company like Bill will be acquired given the uncertainty caused by AI.

Story Continues

Top 5 Initiations:

Bernstein initiated coverage of Honeywell (HON) with a Market Perform rating and $233 price target. While the firm thinks the spinoff of Honeywell Aerospace is "the right strategic move" for the company to re-focus on its automation core, it adds that the remaining business units are distinct types of automation without significant technology and customer overlap. Bernstein also started coverage of Rockwell Automation (ROK) and Carrier Global (CARR) with Market Perform ratings. Bernstein initiated coverage of Vertiv (VRT) with an Outperform rating and $416 price target. The firm says cites the company's "robust earnings power" for the Outperform rating. Bernstein also started coverage of Emerson (EMR), Trane (TT) and Johnson Controls (JCI) with Outperform ratings. Bernstein initiated coverage of 3M (MMM) with an Underperform rating and $131 price target. While the analyst thinks 3M leadership have done "a great job unlocking value with the transformation so far," the firm also worries that re-igniting the innovation engine will be "harder than expected" and adds that PFAS liabilities "refuse to disappear." Piper Sandler initiated coverage of SharkNinja (SN) with an Overweight rating and $150 price target. The company has an "impressive track record" of new innovations through both product launches and category expansions, the firm tells investors in a research note. Morgan Stanley initiated coverage of Blackstone Digital (BXDC) with an Equal Weight rating and $23 price target. The company offers exposure to a "large and growing" data center market, but its return profile is "highly dependent" on capital markets execution and acquisition discipline, the firm tells investors in a research note.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

GSK (LSE:GSK) has agreed to acquire US biotech Nuvalent in a deal valued at US$10.6b. The transaction would add two late stage tyrosine kinase inhibitors for non small cell lung cancer to GSK's oncology portfolio. Both therapies are under regulatory review with anticipated near term launches.

GSK is a global pharmaceuticals company with a growing focus on specialty medicines, and this deal places oncology more clearly at the center of that effort. By adding Nuvalent's late stage lung cancer candidates, GSK is expanding beyond areas such as its hepatitis B franchise and broadening the mix of assets in its late stage pipeline. For investors, this is a sizable move that sits alongside existing vaccines and specialty drug lines.

Management has indicated that the Nuvalent acquisition is expected to contribute to revenue from 2027, which highlights the time horizon involved. The deal also suggests that GSK is prepared to deploy significant capital into late stage, high impact therapies, which may influence how investors think about its future earnings mix and risk profile within oncology and specialty medicines.

Stay updated on the most important news stories for GSK by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on GSK.LSE:GSK Earnings & Revenue Growth as at Jun 2026

We've flagged 3 risks for GSK. See which could impact your investment.

The Nuvalent deal points to GSK leaning harder into oncology as a second pillar alongside vaccines and infectious disease. By paying US$10.6b and offering a 40% premium in cash, GSK is effectively swapping balance sheet flexibility for late-stage lung cancer assets that already have US Food and Drug Administration target decision dates in 2026. For you as an investor, that means a clearer line of sight to potential product launches compared with earlier-stage acquisitions. Management has also said the acquisition is expected to start contributing to revenue from 2027, which fits with comments that Nuvalent will be accretive to core operating profit before earnings per share, where there is expected to be low single digit dilution until 2028. In the context of earlier partnerships in hepatitis B and liver disease, this move suggests GSK is comfortable using both collaborations and large acquisitions to fill pipeline gaps, particularly in cancer where peers such as AstraZeneca, Roche and Bristol Myers Squibb are active.

Story Continues

How This Fits Into The GSK Narrative

This acquisition supports the existing view that GSK is leaning into specialty medicines, since late-stage lung cancer therapies sit squarely in the oncology and high value biologic segment highlighted in the narrative. The sizeable cash and debt-funded consideration could challenge assumptions around future free cash flow and net debt in the narrative, especially as GSK also faces legal and pricing pressures. The specific focus on tyrosine kinase inhibitors for non small cell lung cancer and Nuvalent's preclinical portfolio is not fully captured in the broader discussion of oncology momentum that centers on Jemperli and other existing assets.

Knowing what a company is worth starts with understanding its story.Check out one of the top narratives in the Simply Wall St Community for GSK to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

⚠️ GSK is taking on low single digit core earnings per share dilution until 2028 from the Nuvalent deal, so there is execution risk if the acquired drugs or earlier pipeline do not progress as expected. ⚠️ Lung cancer is a crowded field with large competitors such as AstraZeneca, Merck and Roche, so pricing, reimbursement and differentiation for zidesamtinib, neladalkib and the third asset will be important. 🎁 The two lead Nuvalent therapies already have Breakthrough Therapy and Orphan Drug designations and US FDA target decision dates in 2026, which gives GSK potential near term additions to its oncology portfolio. 🎁 Adding three lung cancer products in advanced development complements GSK's existing oncology drugs and may help diversify future revenue sources across more tumor types and mechanisms.

What To Watch Going Forward

From here, keep an eye on the tender offer progress, the timing of deal closing and any updates from the planned M&A call. Once the acquisition completes, the next milestones will be the US FDA decisions for zidesamtinib and neladalkib, any regulatory feedback in other regions, and how GSK positions these therapies against established lung cancer regimens. It is also worth tracking management commentary on integration costs, use of debt facilities and how Nuvalent fits alongside existing oncology assets in terms of commercial focus and capital allocation priorities.

To ensure you're always in the loop on how the latest news impacts the investment narrative for GSK, head to the community page for GSK to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GSK.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der britische Pharma-Konzern GSK plc hat eine endgültige Vereinbarung geschlossen, um den Bostoner klinischen Entwickler Nuvalent, Inc. für 10,6 Milliarden Dollar in bar zu übernehmen. Die Transaktion stellt den zweitgrößten Biopharma-Übernahme des Jahres dar und bietet GSK einen sofortigen, hohen Wert im Zielmarkt für nicht kleine Zell-Lungenkrebs. Der Deal umfasst drei Produktlinien, darunter zwei spät-stufige, potenziell beste-in-Klasse-Tyrosinkinase-Inhibitoren unter Prioritätsprüfung durch die FDA, mit regulatorischen Genehmigungsentscheidungen bis zum Ende des Jahres geplant.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. in a deal valued at $10.6 billion (7.9 billion pounds), adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise.

Most Read from Bloomberg

House Republican Says Hegseth's D-Day Remarks 'Inappropriate' LA Mayor Race Flips as Socialist Beats Reality TV Star Pratt Trump Says He, Not Congress, Is in Charge of Kennedy Center in Reversal Trump's $100,000 H-1B Visa Application Fee Rejected by Judge Chip Stocks Rally in AI Trade Revival After Plunge: Markets Wrap

GSK will pay $124 a share in cash for Nuvalent, according to a statement Tuesday, a 40% premium over the Cambridge, Massachusetts-based company's closing share price on Monday. It marks a significant expansion of GSK's cancer portfolio, which has been slowly growing since the British drugmaker returned to the disease space in 2019, as well as the first major acquisition for Chief Executive Officer Luke Miels.

Since taking over at the start of this year, Miels has been working to revitalize GSK, which doesn't have a history of risk-taking and has long struggled to allay investors' fears about the drugs it has in development.

GSK shares fell as much as 3% in early trading in London. The stock is up by around 23% over the past 12 months.

Nuvalent designs precisely-targeted therapies for oncology patients including lung cancer. Its shares have declined by 12% this year, giving it a market value of almost $7 billion.

Two of the medicines GSK is acquiring are in late-stage trials, with the US Food and Drug Administration expected to decide on regulatory approval later this year. Both could be blockbuster medicines if approved, GSK said.

The Nuvalent deal won't impact GSK's guidance for the year, and it's expected to contribute to revenue growth from 2027, according to the statement.

The two leading drugs from Nuvalent treat non-small-cell lung cancer patients that have specific mutations. These mutations usually affect people who didn't smoke.

The fortunes of GSK and rival British drugmaker AstraZeneca Plc diverged in 2014 as Astra CEO Pascal Soriot worked to make the company a cancer drug powerhouse.

GSK meanwhile divested its oncology portfolio in an asset swap with Novartis in 2014. Miels, a protégé of Soriot, left Astra acrimoniously, with the company suing him in 2017, alleging he was in violation of his employment agreement. The two companies settled, with Miels joining GSK later that year.

Story Continues

Well-liked by investors, the pick of Australian Miels to succeed Emma Walmsley as CEO was seen as a move that could rejuvenate GSK. The drugmaker, known for its vaccines, has focused on immunology and HIV as vaccine sales have slowed.

In January, GSK agreed on a $2.2 billion deal to buy US biotech Rapt Therapeutics, which develops treatments for inflammatory and immunologic diseases. The firm secured a pulmonary hypertension drug in another transaction.

The Nuvalent purchase is expected to be completed by the third quarter, pending regulatory approvals. The transaction will be funded mainly through new and existing debt facilities plus cash and won't affect GSK's credit rating, the company said.

--With assistance from Michelle F. Davis.

(Updates with shares in fourth paragraph.)

Most Read from Bloomberg Businessweek

Chinese Diners Will Wait Five Hours for This Conveyor-Belt Sushi SpaceX IPO Forces Investors to Bet on Musk's Entangled AI Empire Men in Blazers Is Coming to Take Over the World Cup Where's the Global Economic Meltdown? What Trump Delivered for Amazon

©2026 Bloomberg L.P.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die britische Pharmafirma GSK (LSE:GSK) und ihr Partner Chia Tai Tianqing haben positive Daten für das Medikament Bepirovirsen in der Behandlung von chronischer Hepatitis B vorgestellt. Die Ergebnisse unterstützen die Aussicht auf eine funktionelle Heilung und haben weltweit die Aufmerksamkeit regulatorischer Behörden erregt. Ein kommerzielles Zusammenarbeitssystem wurde eingerichtet, um Bepirovirsen in China zu lancieren, wo ein großes Patientenpotenzial besteht.

Für Investoren, die LSE:GSK verfolgen, liegt diese Aktualisierung an der Schnittstelle von Impfstoffen, Spezialmedikamenten und Infektionskrankheitsforschung, die für das Unternehmen zentral sind. Chronische Hepatitis B betrifft Millionen weltweit und erfordert typischerweise eine lebenslange antivirale Therapie, sodass jeder Fortschritt in Richtung einer funktionellen Heilung innerhalb der breiteren Pharmaindustrie auffällt.

Zukünftig werden Entscheidungen von regulatorischen Behörden und die Umsetzung des chinesischen kommerziellen Zusammenarbeitssystems wichtige Punkte sein, an denen sich Investoren orientieren sollten. Darüber hinaus wird es interessant sein zu sehen, wie GSK über Zugang und Preisgestaltung informiert.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Gilead Sciences, Inc. (GILD) hat positive Ergebnisse aus der spät-stufigen IDEAL-Studie in Patienten mit primärer bilärer Cholangitis (PBC) vorgestellt. Die Studie zeigte, dass Livdelzi (Seladelpar) die Proportionszahl der Patienten erhöht hat, die nach 52 Wochen eine Normalisierung der alkalischen Phosphatase (ALP) erreicht haben, im Vergleich zum Placebo.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die GSK-Spezialmedizin-Business hat sich zum Hauptwachstumsmotor der Firma entwickelt und macht mehr als 40 % des Gesamtumsatzes aus. Der Bereich umfasst vier Kernbereiche: Atemwegserkrankungen, Immunologie & Entzündung (RI&I), Onkologie und HIV. Die Umsätze des Spezialmedizin-Bereichs stiegen im ersten Quartal 2026 um 14 % gegenüber dem Vorjahr auf 3,2 Mrd. Pfund und wurden durch ein Doppelstelliges Wachstum in allen Therapiebereichen getrieben, HIV, RI&I und Onkologie. Produkte wie Nucala und Dovato sind wichtige Top-Linientreiber, während neue langwirkende HIV-Medikamente wie Cabenuva und Apretude sowie neue Onkologie-Drugs wie Jemperli und Ojjaara auch starke Patienten-Nachfrage aufweisen und zum Umsatzwachstum beitragen. GSK erwartet, dass die Verkaufszahlen im Spezialmedizin-Bereich bei einem niedrigen Doppelstelliges Wachstumsrate bei CER in 2026 liegen werden.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die TV-Persönlichkeit Michelle Visage unterstützt die Aufklärung über wichtige Unterschiede bei der langwirkenden injizierbaren PrEP. Mehr Informationen und Ressourcen für Menschen, die von PrEP profitieren könnten, sind auf GetPrEPWisdom.com verfügbar.